[{"orgOrder":0,"company":"Ribocure Pharmaceuticals","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ribo Partners with Boehringer Ingelheim to Develop New Treatments for People with Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform"}]
Find Clinical Drug Pipeline Developments & Deals by Ribocure Pharmaceuticals
The collaboration aims to develop novel treatments for NASH/MASH by using Ribo's experience in the discovery and clinical development of siRNA therapeutics with Boehringer's commitment to improving the lives of people living with cardiovascular, renal and metabolic diseases.